Co-PI: Erica Clinkenbeard, Kenneth White
Agency: Keryx Biopharmaceuticals, Inc.
PI: Erica Clinkenbeard
Agency: Indiana University Center for Translational Sciences Institute Biomedical Research Grant
Clinkenbeard EL, Noonan M, Thomas J, Ni P, Hum JM, Aref M, Swallow E, Moe S, Allen MR. White EK. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD. JCI Inisght (accepted).
Hum JM, O’Bryan LM, Tatiparthi AK, Clinkenbeard EL, Ni P, Cramer MS, Bhaskaran M, Johnson RL, Wilson JM, Smith RC, White KE. Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy. Journal of Applied Physiology (accepted)
Clinkenbeard EL*, Hanudel MR*, Stayrook KR*, Appaiah HM, Farrow EG, Cass TA, Summers LJ, Ip CS, Hum JM, Thomas JC, Ivan M, Richine BM, Chan RJ, Clemens TL, Schipani E, Sabbagh Y, Xu L, Srour EF, Alvarez MB, Kacena MA, Salusky IB, Ganz T, Nemeth E, White KE. (*co-first authors). Erythropoietin stimulates murine and human Fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica. 2017 Nov; 102(11):e427-430.
Hum JM, O’Bryan LM, Tatiparthi AK, Cass TA, Clinkenbeard EL, Cramer MS, Bhaskaran M, Johnson RL, Wilson JM, Smith RC, White KE. Chronic Hyperphosphatemia and Vascular Calcification are Reduced by Stable Delivery of Soluble Klotho. J Am Soc Nephrol. 2017 Apr; 28(4):1162-1174.
The lab team also includes Daniel Edwards III (Research Technician).